NovaBay Pharmaceuticals Inc (NBY)vsNovartis AG ADR (NVS)

NBY

NovaBay Pharmaceuticals Inc

NYSE MKT

$1.95

+22.64%

HEALTHCARE · Cap: $51.92M

NVS

Novartis AG ADR

NYSE

$148.38

-0.99%

HEALTHCARE · Cap: $273.77B

⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 549094% more annual revenue ($56.58B vs $10.30M). NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).

NBY

Hold

out of 100

Grade: D

Growth: 3.7Profit: 4.5Value: 5.0Quality: 4.5

Piotroski: 1/9Altman Z: -82.66

NVS

Hold

out of 100

Grade: D+

Growth: 3.3Profit: 9.0Value: 3.3Quality: 4.5

Piotroski: 4/9Altman Z: 1.96

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for NBY.

NVSSignificantly Overvalued (-62.1%)

Margin of Safety

-62.1%

Fair Value

$91.39

Current Price

$148.38

$56.99 premium

UndervaluedFair: $91.39Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NBY1 strengths · Avg: 10.0/10

Operating MarginProfitability

350.1%10/10

Strong operational efficiency at 350.1%

NVS5 strengths · Avg: 9.4/10

Market CapQuality

$273.77B10/10

Mega-cap, among the largest globally

Return on EquityProfitability

35.1%10/10

Every $100 of equity generates 35 in profit

Operating MarginProfitability

30.5%10/10

Strong operational efficiency at 30.5%

Profit MarginProfitability

23.9%9/10

Keeps 24 of every $100 in revenue as profit

Free Cash FlowQuality

$2.87B8/10

Generating 2.9B in free cash flow

Areas to Watch

NBY4 concerns · Avg: 3.3/10

EPS GrowthGrowth

0.0%4/10

0.0% earnings growth

Market CapQuality

$51.92M3/10

Smaller company, higher risk/reward

Profit MarginProfitability

0.0%3/10

0.0% margin — thin

Piotroski F-ScoreQuality

1/93/10

Weak financial health signals

NVS4 concerns · Avg: 2.8/10

Altman Z-ScoreHealth

1.964/10

Grey zone — moderate risk

Debt/EquityHealth

1.223/10

Elevated debt levels

PEG RatioValuation

3.932/10

Expensive relative to growth rate

Revenue GrowthGrowth

-0.7%2/10

Revenue declined 0.7%

Comparative Analysis Report

WallStSmart Research

Bull Case : NBY

The strongest argument for NBY centers on Operating Margin.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.

Bear Case : NBY

The primary concerns for NBY are EPS Growth, Market Cap, Profit Margin.

Bear Case : NVS

The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.

Key Dynamics to Monitor

NBY profiles as a value stock while NVS is a declining play — different risk/reward profiles.

NVS carries more volatility with a beta of 0.49 — expect wider price swings.

NVS is growing revenue faster at -0.7% — sustainability is the question.

NVS generates stronger free cash flow (2.9B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (49/100 vs 40/100), backed by strong 23.9% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

NovaBay Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

NovaBay Pharmaceuticals, Inc., a medical device company, develops products for the eye care markets in the United States and internationally. The company is headquartered in Emeryville, California.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Compare with Other BIOTECHNOLOGY Stocks

NBY vs VRTX NBY vs REGN NBY vs ARGX NBY vs ALNY NBY vs RVMD NVS vs VRTX NVS vs REGN NVS vs ARGX NVS vs ALNY NVS vs RVMD

Want to dig deeper into these stocks?

Full NBY Analysis →Full NVS Analysis →